Abstract
Ovarian cancer (OC) is one of the deadliest cancers, with high relapse and resistance rates despite current treatments. The enzyme nicotinamide phosphoribosyltransferase (NAMPT), particularly in its extracellular form (eNAMPT), plays a key role in tumor processes including DNA repair, proliferation, metastasis, and drug resistance. However, its role in OC remains poorly understood. This project aims to investigate the pathological role of eNAMPT in OC, hypothesizing that it promotes aggressive tumor phenotypes via EMT and stemness modulation. Preliminary data show elevated eNAMPT levels in OC ascitic fluid, indicating its potential as a biomarker. The study is structured in four work packages: WP1 evaluates eNAMPT levels in patient samples and correlates them with clinical outcomes; WP2 and WP3 explore its function using in vitro and in vivo models; WP4 tests the efficacy of an anti-eNAMPT monoclonal antibody (C269). The ultimate goal is to assess eNAMPT as a therapeutic target in OC.
Project details
Unibo Team Leader: Gloria Ravegnini
Unibo involved Department/s:
Dipartimento di Farmacia e Biotecnologie
Coordinator:
ALMA MATER STUDIORUM - Università di Bologna(Italy)
Total Eu Contribution: Euro (EUR) 224.000,00
Total Unibo Contribution: Euro (EUR) 112.000,00
Project Duration in months: 24
Start Date:
16/10/2023
End Date:
28/02/2026
